Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the first quarter ended March 31, 2024 and provided an update on recent clinical development pipeline and other corporate developments.
- 2024 AACR Annual Meeting: Prelude participated in the 2024 American Association for Cancer Research Annual Meeting, presenting three preclinical poster presentations.
- Corporate Updates: In April 2024, Prelude appointed Sean Brusky to the newly created position of Chief Business Officer.
- Additionally, in April 2024, Prelude appointed Robert Doody to the newly created position of Senior Vice President, Investor Relations.
- We expect our R&D expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.